Search Results - Oucheva, Radka

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 “ISTAHIT” study

    High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first r... by PETZER, Andreas L, WOLF, Dominik, GERCHEVA, Liana, STOJANOVIC, Aleksandar, PEYTCHEV, Dontcho, TZVETKOV, Nikolay, GRINIUTE, Rasa, OUCHEVA, Radka, ULMER, Hanno, KWAKKELSTEIN, Marthin, RANCATI, Francesca, GASTL, Guenther, FONG, Dominic, LION, Thomas, DYAGIL, Irina, MASLIAK, Zvenyslava, BOGDANOVIC, Andrija, GRISKEVICIUS, Laimonas, LEJNIECE, Sandra, GORANOV, Stefan

    Published in Haematologica (Roma)
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    High Dose Imatinib Induction Therapy (800 mg/day, 6 Months) In Pre-Treated Chronic Phase CML Patients Improves Cytogenetic and Molecular Responses but Does Not Improve Overall and Progression Free Survival – Final Results of the CELSG Phase III CML11 “ISTAHIT” Trial

    High Dose Imatinib Induction Therapy (800 mg/day, 6 Months) In Pre-Treated Chronic Phase CML Patients Improves Cytogenetic and Molecular Responses but Does Not Improve Overall and... by Petzer, Andreas L, Fong, Dominic, Lion, Thomas, Dyagil, Irina, Masliak, Zvenyslava, Bogdanovic, Andrija, Griskevicius, Laimonas, Lejniece, Sandra, Goranov, Stefan, Gercheva, Liana, Stojanovic, Aleksandar, Peytchev, Dontcho, Tzetkov, Nikolay, Griniute, Rasa, Oucheva, Radka, Grubinger, Thomas, Kwakkelstein, Marthin, Rancati, Francesca, Gastl, Günther A, Wolf, Dominik

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    CELSG CML 11 “ISTAHIT” Phase III Study – Planned Interim Analysis: High Doses of Imatinib Mesylate (800mg/day) Significantly Improve Rates of Major and Complete Cytogenetic Remissions (MCR, CCR) in Pretreated Ph+/BCR-ABL+ CML Patients in Chronic Phase

    CELSG CML 11 “ISTAHIT” Phase III Study – Planned Interim Analysis: High Doses of Imatinib Mesylate (800mg/day) Significantly Improve Rates of Major and Complete Cytogenetic Remissi... by Petzer, Andreas L., Wolf, Dominik, Fong, Dominic, Lion, Thomas, Dyagil, Irina, Masliak, Zvenyslava, Boskovic, Darinka, Griskevicius, Laimonas, Lejniece, Sandra, Goranov, Stefan, Gercheva, Liana, Stojanovic, Aleksandar, Peytchev, Dontcho, Tzvetkov, Nikolay, Griniute, Rasa, Oucheva, Radka, Ulmer, Hanno, Kwakkelstein, Marthin, Fincato, Gianluca, Gastl, Guenther

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    A New Variant Chromosomal Translocation t(2;2)(p23;q23) in CD30+/Ki-1+ Anaplastic Large Cell Lymphoma

    A New Variant Chromosomal Translocation t(2;2)(p23;q23) in CD30+/Ki-1+ Anaplastic Large Cell Lymphoma by Mitev, Lubomir, Christova, Svetlana, Hadjiev, Evgeni, Guenova, Margarita, Oucheva, Radka, Valkov, Ivan, Manolova, Yanka

    Published in Leukemia & lymphoma
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: